Regeneron Pharmaceuticals, Inc. (REGN)
NASDAQ: REGN · Real-Time Price · USD
632.90
+12.76 (2.06%)
At close: Jun 26, 2026, 4:00 PM EDT
631.38
-1.52 (-0.24%)
After-hours: Jun 26, 2026, 7:57 PM EDT
Regeneron Pharmaceuticals Employees
Regeneron Pharmaceuticals had 15,410 employees as of December 31, 2025. The number of employees increased by 304 or 2.01% compared to the previous year.
Employees
15,410
Change (1Y)
304
Growth (1Y)
2.01%
Revenue / Employee
$968,177
Profits / Employee
$287,047
Market Cap
64.39B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 15,410 | 304 | 2.01% |
| Dec 31, 2024 | 15,106 | 1,656 | 12.31% |
| Dec 31, 2023 | 13,450 | 1,599 | 13.49% |
| Dec 31, 2022 | 11,851 | 1,483 | 14.30% |
| Dec 31, 2021 | 10,368 | 1,245 | 13.65% |
| Dec 31, 2020 | 9,123 | 1,023 | 12.63% |
| Dec 31, 2019 | 8,100 | 700 | 9.46% |
| Dec 31, 2018 | 7,400 | 1,200 | 19.35% |
| Dec 31, 2017 | 6,200 | 800 | 14.81% |
| Dec 31, 2016 | 5,400 | 1,100 | 25.58% |
| Dec 31, 2015 | 4,300 | 1,375 | 47.01% |
| Dec 31, 2014 | 2,925 | 585 | 25.00% |
| Dec 31, 2013 | 2,340 | 390 | 20.00% |
| Dec 31, 2012 | 1,950 | 246 | 14.44% |
| Dec 31, 2011 | 1,704 | 309 | 22.15% |
| Dec 31, 2010 | 1,395 | 366 | 35.57% |
| Dec 31, 2009 | 1,029 | 110 | 11.97% |
| Dec 31, 2008 | 919 | 237 | 34.75% |
| Dec 31, 2007 | 682 | 109 | 19.02% |
| Dec 31, 2006 | 573 | -15 | -2.55% |
| Dec 31, 2005 | 588 | -142 | -19.45% |
| Dec 31, 2004 | 730 | 86 | 13.35% |
| Dec 31, 2003 | 644 | -25 | -3.74% |
| Dec 31, 2002 | 669 | 94 | 16.35% |
| Dec 31, 2001 | 575 | 84 | 17.11% |
| Dec 31, 2000 | 491 | 54 | 12.36% |
| Dec 31, 1999 | 437 | 66 | 17.79% |
| Dec 31, 1998 | 371 | 101 | 37.41% |
| Dec 31, 1997 | 270 | 27 | 11.11% |
| Dec 31, 1996 | 243 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| BeOne Medicines AG | 12,000 |
| BioNTech SE | 7,807 |
| Vertex Pharmaceuticals | 6,400 |
| Moderna | 4,700 |
| Incyte | 2,844 |
| Alnylam Pharmaceuticals | 2,500 |
| argenx SE | 1,863 |
| Insmed | 1,664 |
REGN News
- 2 days ago - Regeneron to Report Second Quarter 2026 Financial and Operating Results and Host Conference Call and Webcast - GlobeNewsWire
- 5 days ago - Apogee acquisition is ‘net negative’ for Regeneron, says RBC Capital - TheFly
- 5 days ago - Regeneron announces FDA, EMA accept cemdisiran submissions for review - TheFly
- 5 days ago - Cemdisiran Regulatory Submissions Accepted for Review by FDA and EMA for the Treatment of Generalized Myasthenia Gravis (gMG) - GlobeNewsWire
- 15 days ago - Regeneron Pharmaceuticals Transcript: AGM 2026 - Transcripts
- 15 days ago - Regeneron Pharmaceuticals Slides: FY 2026 - Filings
- 19 days ago - Regeneron Pharmaceuticals Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026 - Transcripts
- 23 days ago - Regeneron to Highlight Progress Across Its Metabolic Disease, Ophthalmology and Rare Disease Pipelines at ADA and ENDO - GlobeNewsWire